CymitQuimica logo
PD-1/PD-L1

PD-1/PD-L1

Gli inibitori di PD-1/PD-L1 sono inibitori del checkpoint immunitario che bloccano l'interazione tra la proteina di morte cellulare programmata 1 (PD-1) sui linfociti T e il suo ligando PD-L1 sulle cellule tumorali. Questa interazione sopprime normalmente la risposta immunitaria e permette alle cellule tumorali di sfuggire al riconoscimento immunitario. Inibendo PD-1/PD-L1, questi inibitori potenziano la capacità del sistema immunitario di riconoscere e distruggere le cellule tumorali, inducendo apoptosi e regressione tumorale. Gli inibitori di PD-1/PD-L1 sono fondamentali nella ricerca sull'immunoterapia e nel trattamento del cancro. Presso CymitQuimica, offriamo una gamma di inibitori di PD-1/PD-L1 di alta qualità per supportare la tua ricerca in immuno-oncologia, apoptosi e terapia del cancro.

Trovati 182 prodotti per "PD-1/PD-L1".

prodotti per pagina.
  • Penpulimab

    CAS:
    Penpulimab is a monoclonal antibody targeting PD-1 with antitumor activity, used in studies of pancreatic cancer.
    Purezza:96.8% (SEC-HPLC) - 96.8% (SEC-HPLC)
    Colore e forma:Transparent Liquid
    Peso molecolare:145.14 kDa (Predicted)
  • Sintilimab

    CAS:
    Sintilimab (IBI308), an IgG4 monoclonal antibody, blocks PD-1, enhancing T-cell anti-tumor response; treats Hodgkin's, lung, and esophageal cancers.
    Purezza:> 95% - >95.0% (SDS-PAGE); 95.0% (SEC-HPLC)
    Colore e forma:Liquid
    Peso molecolare:143.78 kDa (Predicted)
  • Zimberelimab

    CAS:
    Zimberelimab (GLS-010) is a humanized antibody targeting PD-1, with anticancer activity.
    Purezza:95%
    Colore e forma:Transparent Liquid
    Peso molecolare:146.54 kDa (Predicted)
  • AUNP-12 acetate


    AUNP-12 acetate is a polypeptide inhibitor of PD-1 that is equivalent to PD-1 and PD-2 in inhibiting lymphocyte proliferation and effector fuction, in addition
    Formula:C144H230N40O50
    Purezza:95.07% - 99.29%
    Colore e forma:White Solid
    Peso molecolare:3321.61
  • Durvalumab

    CAS:
    Durvalumab is a humanized antibody for cancer, inhibiting PD-L1/PD-1 and CD80 interactions at very low concentrations.
    Purezza:97.2% (SDS-PAGE); 95.3% (SEC-HPLC) - 97.7% (SDS-PAGE); 99.59% (SEC-HPLC)
    Colore e forma:Transparent Liquid
    Peso molecolare:146.03 kDa (Predicted)
  • BMS-1001 hydrochloride

    CAS:
    BMS-1001 hydrochloride is an orally active inhibitor of human PD-1/PD-L1 immune checkpoint with low-toxicity in cells.BMS-1001 alleviates the inhibitory effect
    Formula:C35H35ClN2O7
    Purezza:97.36%
    Colore e forma:Solid
    Peso molecolare:631.115
  • Budigalimab

    CAS:
    Budigalimab (ABBV 181) is a humanized monoclonal antibody targeting PD-1 with potential antitumor activity.
    Purezza:97% (SDS-PAGE); 98.8% (SEC-HPLC) - 97% (SDS-PAGE); 98.8% (SEC-HPLC)
    Colore e forma:Transparent Liquid
    Peso molecolare:145.72 kDa (Predicted)
  • Dostarlimab

    CAS:
    Dostarlimab (TSR-042) is an immune checkpoint inhibitor targeting PD-1, blocking its interaction with its ligands PD-L1 and PD-L2.
    Purezza:>95%
    Colore e forma:Transparent Liquid
    Peso molecolare:144.18 kDa (Predicted)
  • Tislelizumab

    CAS:
    Tislelizumab, a PD-1 receptor monoclonal antibody, reduces Fcγ interaction and T cell clearance in advanced squamous NSCLC research.
    Purezza:95.07%
    Colore e forma:Transparent Liquid
    Peso molecolare:145 kDa (Predicted)
  • Ezabenlimab

    CAS:
    Ezabenlimab (BI-754091) is an anti-PD-1 mAb, Kd 6 nM, blocks PD-1/PD-Ls, boosts T-cell IFN-γ, inhibits tumors in vivo.
    Purezza:99.1% (SDS-PAGE); 96.9% (SEC-HPLC) - 99.1% (SDS-PAGE); 96.9% (SEC-HPLC)
    Colore e forma:Transparent Liquid
    Peso molecolare:145.21 kDa (Predicted)
  • Spartalizumab

    CAS:
    "Spartalizumab (PDR001), a humanized IgG4 monoclonal antibody, targets PD-1 to inhibit PD-L1/L2 interactions, useful in ATC research."
    Purezza:SDS-PAGE:95.2%;SEC-HPLC:96.3%
    Colore e forma:Transparent Liquid
    Peso molecolare:145.74 kDa (Predicted)
  • Garivulimab

    CAS:
    Garivulimab (BGB-A333) is a humanized mAb targeting PD-L1 that enhances T-cell anti-tumor activity by blocking the PD-1/PD-L1 pathway.
    Purezza:95%
    Colore e forma:Transparent Liquid
  • TPP-1 TFA


    TPP-1 TFA is a high-affinity PD-L1 inhibitor (KD=95nM) that boosts T-cell function to curb tumor growth.
    Formula:C109H151F3N34O34S2
    Colore e forma:Solid
    Peso molecolare:2602.69
  • Eciskafusp alfa

    CAS:
    Eciskafusp alfa, a cis-targeted IL2v immunocytokine, acts on programmed cell death 1 (PDCD1, commonly known as PD-1), preferentially targeting antigen-specific
    Purezza:98%
    Colore e forma:Solid
  • Sotiburafusp alfa

    CAS:
    Sotiburafusp alfa is a humanized bispecific fusion protein comprising a VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) connected
    Purezza:98%
    Colore e forma:Solid
  • PD-1/PD-L1-IN-52


    PD-1/PD-L1-IN-52 (Compound Ⅲ-5) is an orally active inhibitor of PD-1/PD-L1 interaction, exhibiting an IC50 of 109.9 nM. It demonstrates antitumor activity in a C57BL/6 mouse model of MC38 colon carcinoma cells expressing human PD-1, achieving a tumor growth inhibition (TGI) rate of 49.6%.
    Colore e forma:Odour Solid
  • PD-1/PD-L1-IN-9

    CAS:
    PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction.
    Formula:C22H24N2O2
    Purezza:99.92%
    Colore e forma:Solid
    Peso molecolare:348.4382
  • PD-1/PD-L1-IN-48


    PD-1/PD-L1-IN-48 (compound HD10) is an effective inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 of 3.1 nM. It plays a vital role in cancer research.
    Colore e forma:Odour Solid
  • MS1-96


    MS1-96 is an orally active PD-L1 (programmed death-ligand 1) degrader. It effectively reduces PD-L1 protein expression levels in various colorectal cancer (CRC) cell lines. The compound loses its ability to induce PD-L1 degradation upon HIP1R knockdown. MS1-96 binds directly to PD-L1 (KD= 2.58 μM) and enhances the interaction between HIP1R and PD-L1, altering PD-L1's intracellular transport in clathrin-coated vesicles. Additionally, MS1-96 induces abnormal N-glycosylation of PD-L1, leading to protein instability and accelerated lysosome-mediated degradation. MS1-96 is applicable for colorectal cancer research.
  • HLX43


    HLX43 is an ADC targeting PD-L1 with DAR=8 and a cleavable linker that releases C24, possessing both immune blockade and bystander killing effects.
    Purezza:95% - 98.30% (SEC-HPLC)
    Peso molecolare:153.06 kDa (Predicted)